ZLc002 Chemical Properties

Boiling point:

350.1±22.0 °C(Predicted)

Density 

1.115±0.06 g/cm3(Predicted)

storage temp. 

Store at -20°C

solubility 

DMSO: 46 mg/mL (198.92 mM);Ethanol: 46 mg/mL (198.92 mM)

pka

12.22±0.46(Predicted)

form 

Solid

color 

Off-white to light yellow

Water Solubility 

Water: 46 mg/mL (198.92 mM)

InChI

InChI=1S/C10H17NO5/c1-6(2)9(10(14)16-4)11-7(12)5-8(13)15-3/h6,9H,5H2,1-4H3,(H,11,12)/t9-/m0/s1

InChIKey

BWPKYDAJBOUZDX-VIFPVBQESA-N

SMILES

C(OC)(=O)[C@H](C(C)C)NC(=O)CC(OC)=O

ZLc002 Usage And Synthesis

Biological Activity

ZLc-002 is a selective inhibitor of nNOS-Capon coupling. ZLc-002 suppresses inflammatory nociception and chemotherapy-induced neuropathic pain.

Biological Functions

ZLc002, a putative small-molecule inhibitor of nNOS interaction with NOS1AP, suppresses inflammatory nociception and chemotherapy-induced neuropathic pain and synergizes with paclitaxel to reduce tumor cell viability. It could disrupt binding between nNOS and NOS1AP using ex-vivo, in vitro, and purified recombinant systems. In vitro, ZLc002 reduced coimmunoprecipitation of full-length NOS1AP and nNOS in cultured neurons and HEK293T cells co-expressing full-length nNOS and NOS1AP[1].

References

[1] Lee WH, et al. Mol Pain. 2018 Jan-Dec;14:1744806918801224.
[2] Wan-Hung Lee. “ZLc002, a putative small-molecule inhibitor of nNOS interaction with NOS1AP, suppresses inflammatory nociception and chemotherapy-induced neuropathic pain and synergizes with paclitaxel to reduce tumor cell viability.” Molecular Pain 14 (2018): 1744806918801224.